Corporate Information – Page 38 – Alligator Bioscience

2017-09-13

Regulatory

Alligator Bioscience signs immunotherapy research collaboration agreement for 4-1BB

Research team to be led by Professor Ignacio Melero, Center for Applied Medical Research (CIMA) and Clínica Universidad de Navarra, Spain Lu ...

2017-08-17

Regulatory

Novel Bispecific Antibody Targeting Biological Pathway Implicated in Multiple Solid Tumor Indications Seattle, WA, and Lund, Sweden – August ...

2017-08-07

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX), a biotechnology company developing tumor-directed immunotherapies for canc ...

2017-07-21

Regulatory

Strategic partnership will advance development of a novel bispecific immuno-oncology antibody targeting compelling biological pathway implic ...

2017-06-12

Regulatory

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX), a biotechnology company developing antibody-based pharmaceuticals for canc ...

2017-05-04

Regulatory

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) today presented new pre-clinical data on the CD40 agonistic immuno-oncology ...

2017-05-02

Today, on May 2, 2017, an annual shareholders’ meeting was held in Alligator Bioscience AB. A summary of the resolutions adopted follows bel ...

2017-04-28

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) announced today that it will present new pre-clinical data on the CD40 agon ...

2017-03-23

Regulatory

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) announced today that the first phase I study with ADC-1013, a human, ...